List of Excipients in Branded Drug BETAMETHASONE DIPROPIONATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E Fougera & Co a division of Fougera Pharmaceuticals LLC	BETAMETHASONE DIPROPIONATE	betamethasone dipropionate	0168-0056	MINERAL OIL
E Fougera & Co a division of Fougera Pharmaceuticals LLC	BETAMETHASONE DIPROPIONATE	betamethasone dipropionate	0168-0056	PETROLATUM
A-S Medication Solutions	BETAMETHASONE DIPROPIONATE	betamethasone dipropionate	50090-0235	CETOSTEARYL ALCOHOL

Generic Drugs Containing BETAMETHASONE DIPROPIONATE

Company	Ingredient	NDC	Excipient
E Fougera & Co a division of Fougera Pharmaceuticals Inc	betamethasone dipropionate	0168-0055	CETOSTEARYL ALCOHOL
E Fougera & Co a division of Fougera Pharmaceuticals Inc	betamethasone dipropionate	0168-0055	CHLOROCRESOL
E Fougera & Co a division of Fougera Pharmaceuticals Inc	betamethasone dipropionate	0168-0055	MINERAL OIL

What are the Most Frequently-Used Excipients in BETAMETHASONE DIPROPIONATE?

# Of NDCs	Excipient
1	AQUA
1	BUTYLATED HYDROXYTOLUENE
1	CARBOMER 940

Betamethasone Dipropionate Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

Betamethasone dipropionate is a mature, high-potency topical corticosteroid with limited molecule-level differentiation and substantial opportunity at the formulation level. The strongest commercial strategies focus on vehicle performance, skin tolerability, sensory properties, delivery format, packaging, and regulatory pathways rather than new chemical entities. Ointments, creams, lotions, gels, and sprays can target different patient and prescriber needs, but each format creates different requirements for solubility, particle size, preservative control, dermal delivery, and comparative bioequivalence.

What is the formulation profile of betamethasone dipropionate?

Betamethasone dipropionate is a fluorinated corticosteroid used for inflammatory and pruritic dermatoses. It has the molecular formula C28H37FO7 and a molecular weight of approximately 504.59 g/mol. The drug is practically insoluble in water, making suspension-based semisolids and solvent-assisted systems more practical than simple aqueous solutions.[1]

Attribute	Formulation implication
Active ingredient	Betamethasone dipropionate
Common topical strength	0.05%
Route	Topical dermal
Water solubility	Very low
Pharmacologic class	Potent to super-high-potency topical corticosteroid, depending on vehicle and product
Main dosage forms	Ointment, cream, lotion, gel, spray
Key performance variables	Particle size, drug distribution, vehicle evaporation, skin partitioning, rheology, occlusivity
Primary safety constraints	Skin atrophy, hypothalamic-pituitary-adrenal-axis suppression, systemic absorption, ocular exposure

The same nominal concentration does not ensure the same clinical or regulatory performance. Vehicle composition, active-particle size, degree of solubilization, application characteristics, and occlusion can change dermal delivery. FDA labeling for augmented betamethasone dipropionate products emphasizes that potency depends on formulation and that use is generally limited by treatment duration, body surface area, and site of application.[2]

Which excipients are most important for betamethasone dipropionate?

The highest-value excipient decisions involve the lipid phase, solvent system, emulsifier package, rheology modifier, preservative system, and packaging interface.

Ointment excipients

Ointments are commercially attractive because they provide strong occlusion and generally support high dermal penetration. Typical excipient classes include:

• White petrolatum or mineral hydrocarbons for occlusion and emollience.
• Mineral oil or related liquid hydrocarbons for spreadability.
• Propylene glycol as a humectant, cosolvent, and penetration-supporting excipient.
• Microcrystalline wax or similar structuring agents for viscosity and temperature stability.
• Antioxidants where required by the selected vehicle and packaging system.

An ointment platform is appropriate when maximum potency and barrier protection are priorities. Its disadvantages are greasiness, poor cosmetic acceptability, transfer to clothing, and lower patient adherence in warm climates or hairy areas.

A commercial opportunity exists for a less greasy ointment with equivalent drug delivery. The formulation must preserve the occlusive function without creating excessive drag, whitening, tack, or residue. Replacing part of the hydrocarbon phase with a lighter emollient can improve skin feel, but changes in drug partitioning and release must be demonstrated rather than assumed.

Cream excipients

Creams offer the broadest commercial market because they balance efficacy, spreadability, and cosmetic acceptability. Common functional categories include:

Excipient function	Candidate categories	Commercial purpose
Continuous phase	Water-in-oil or oil-in-water emulsion	Controls feel, release, and occlusion
Humectant or cosolvent	Propylene glycol, glycerol, polyols	Supports hydration and drug distribution
Oil phase	Mineral oil, esters, fatty alcohols	Improves spreadability and emollience
Emulsifier	Nonionic surfactants, fatty alcohol systems	Stabilizes the emulsion
Thickener	Carbomer, cellulose derivatives, acrylate polymers	Controls viscosity and dose uniformity
Preservative	Phenoxyethanol, parabens, organic acids, other approved systems	Controls microbial growth
Chelator	Disodium edetate or equivalent	Supports preservative and stability performance
Buffer	Phosphate, citrate, or other compatible systems	Controls pH and stability

A cream formulation should minimize sting, irritation, pilling, phase separation, and residue. Propylene glycol can improve solubilization and penetration but may cause irritation in some patients. Alcohols can improve drying and sensory performance but may be unsuitable for fissured, inflamed, or sensitive skin.

The best development target is usually not the highest possible penetration. It is reproducible dermal delivery with acceptable tolerability and a strong patient-use profile.

Lotion and solution systems

Lotions are useful for large surface areas, hairy skin, and scalp application. They spread rapidly and leave less residue than ointments or creams. The main technical challenge is maintaining uniform active distribution when the drug is suspended or only partly solubilized.

A lotion strategy may use:

• Water and a cosolvent system.
• Propylene glycol or another compatible polyol.
• A controlled oil phase.
• Suspending or rheology-modifying polymers.
• Preservatives and chelators.
• A low-foaming surfactant system.

The product must maintain dose uniformity throughout storage and use. Sedimentation, crystal growth, nozzle blockage, and concentration changes during evaporation are key risks. A shake-well instruction can address some suspension issues, but it also introduces patient-use variability.

Gel systems

Gels can provide fast drying and a cleaner sensory profile. They are attractive for scalp, facial, or localized lesions where ointment residue is unacceptable. Potential excipient systems include carbomer, hydroxyethylcellulose, poloxamers, alcohols, and polyols.

The principal development risks are:

• Alcohol-related stinging.
• Polymer incompatibility with electrolytes or preservatives.
• Drug crystallization during storage.
• Excessive drying or irritation.
• Loss of viscosity at elevated temperature.
• Poor dosing control when the gel is dispensed from a tube or pump.

A nonalcoholic gel would offer a meaningful differentiation opportunity, particularly for patients who reject traditional greasy or volatile vehicles.

Spray systems

Sprays can improve application to large or difficult-to-reach areas and reduce direct hand contact. Betamethasone dipropionate spray products use volatile and emulsion-related excipient systems to create a rapidly spreading product.[3]

A spray platform must address:

• Droplet-size distribution.
• Spray pattern and plume geometry.
• Priming and tail-off behavior.
• Container compatibility.
• Valve and actuator performance.
• Flammability where alcohol or propellant is used.
• Uniform dose delivery over the product shelf life.

Sprays have stronger differentiation potential than standard creams, but they require more device and packaging development. The commercial case is strongest in scalp psoriasis, large-area dermatitis, and patient populations with poor adherence to semisolid products.

What formulation attributes should a development program prioritize?

A commercially viable formulation should optimize five attributes:

1. Consistent dermal delivery. The active should remain uniformly distributed, with controlled release from the vehicle.
2. Low irritation. The product should minimize sting, burning, drying, and preservative-related reactions.
3. Acceptable sensory performance. Spreadability, residue, drying time, tack, and odor directly influence adherence.
4. Manufacturing robustness. The formulation should tolerate scale-up, temperature excursions, filling, and long-term storage.
5. Regulatory comparability. The development plan should anticipate FDA requirements for qualitative and quantitative sameness or comparative product performance.

Particle engineering is particularly important. Micronized or otherwise controlled particle-size material can improve content uniformity and change dissolution and skin delivery. The particle-size distribution should be treated as a critical material attribute, not only as a manufacturing specification.

What are the strongest excipient-led commercial opportunities?

Preservative-reduced or preservative-free products

A preservative-reduced cream or ointment could target patients with sensitive skin or a history of contact dermatitis. The commercial value depends on packaging. Airless pumps, unit-dose packaging, or other low-contamination systems may be needed to maintain microbiological quality.

A preservative-free product is not automatically superior. It can increase packaging cost, manufacturing complexity, and in-use contamination risk. The product must demonstrate an appropriate microbiological control strategy under applicable standards, including antimicrobial effectiveness and in-use testing where relevant.[4]

Non-greasy high-potency semisolids

The market has room for a high-potency product with lower residue and faster absorption than conventional petrolatum-heavy ointments. An emulsion or structured emollient system could target patients who discontinue treatment because of greasiness.

The principal risk is an inadvertent increase in systemic or local exposure. A more cosmetically elegant vehicle can increase use frequency or treated surface area, potentially increasing corticosteroid exposure. Labeling, clinical pharmacology, and comparative performance data must support the product profile.

Scalp and hairy-area delivery

Lotions, gels, foams, and sprays are better suited than ointments for scalp and hairy areas. A metered spray or low-residue lotion can provide differentiation without changing the active ingredient.

The product should be evaluated for:

• Spray or pump dose uniformity.
• Hair wetting and residue.
• Drip and run-off.
• Application under hair.
• Flammability and drying time.
• Patient ability to identify treated areas.

Barrier-supportive vehicles

A formulation containing emollients, humectants, and barrier-supportive lipids could position the product for dermatitis patients with xerosis. The commercial claim must remain within the approved corticosteroid indication unless supported through an appropriate regulatory pathway.

Potential components include physiologic lipids, ceramide-related materials, glycerol, and emollient esters. These ingredients may improve tolerability, but they also increase formulation complexity and can affect preservative performance, viscosity, and drug release.

Device-enabled dosing

A pump, metered-dose spray, or unit-dose sachet can address under-application and reduce contamination. Device differentiation is most defensible when it produces a measurable benefit in dose reproducibility, application to difficult sites, or patient adherence.

A device change may trigger combination-product considerations and additional human-factors work. Packaging must also protect against adsorption, evaporation, leakage, and active loss at the container closure interface.

What FDA regulatory pathways apply to new betamethasone dipropionate formulations?

For a conventional topical generic, the likely pathway is an abbreviated new drug application. The applicant must address pharmaceutical equivalence, active-ingredient sameness, product quality, and comparative performance. FDA has developed product-specific guidance and broader recommendations for topical dermatological products, including characterization of Q1, Q2, and Q3 properties.[5]

• Q1 sameness: The same inactive ingredients.
• Q2 sameness: The same inactive ingredients at the same concentrations.
• Q3 similarity: Comparable physical and structural characteristics, such as particle size, globule size, rheology, pH, viscosity, and microstructure.

A novel excipient system may reduce the ability to rely on straightforward Q1/Q2 comparability. A 505(b)(2) application can be relevant when the sponsor seeks approval for a materially different dosage form, delivery system, or clinical use supported by literature and new data. The commercial advantage is potential differentiation; the cost is greater regulatory and clinical burden.

For semisolid products, the development package may include:

• Assay and content uniformity.
• Impurity and degradation profiling.
• Particle-size distribution.
• In vitro release testing.
• In vitro permeation testing.
• Rheology and viscosity.
• Globule or droplet size for emulsions.
• Microstructure.
• Microbial limits and preservative effectiveness.
• Stability under ICH conditions.
• Comparative clinical endpoint or pharmacodynamic data where required.

FDA’s topical dermatological product guidance identifies in vitro release testing as a useful tool for product development and quality assessment, although release testing alone does not establish therapeutic equivalence.[6]

When does betamethasone dipropionate lose exclusivity?

Betamethasone dipropionate is an old active ingredient, and the core molecule is no longer protected by new chemical entity exclusivity in the United States. Commercial exclusivity therefore depends primarily on formulation patents, dosage-form patents, method-of-use claims, trademarks, regulatory exclusivity for a specific product, and manufacturing know-how.

Protection category	Current commercial relevance
Active ingredient patent	Generally expired for this mature corticosteroid
Original product exclusivity	Expired for legacy products
Formulation patents	Potentially relevant for differentiated vehicles or delivery systems
Method-of-use patents	May apply to specific indications, sites, regimens, or combinations
Device and packaging patents	Relevant to sprays, pumps, valves, and metered delivery
Trademark protection	Relevant to brand positioning and substitution resistance
Manufacturing know-how	Often important where particle size, crystallinity, or microstructure controls performance

An Orange Book review should be performed at the specific product level because different betamethasone dipropionate products can have different listings, strengths, dosage forms, and patent records.[7] A formulation sponsor should not assume that the absence of active-ingredient protection eliminates Paragraph IV risk. A generic applicant can still face listed patents covering a vehicle, delivery system, method of treatment, or product configuration.

What Paragraph IV and litigation risks exist?

Paragraph IV risk is generally lower for a standard, long-established cream or ointment than for a branded spray, device-enabled product, or proprietary vehicle. The risk rises when the reference product has:

• A live formulation patent.
• A listed method-of-use patent.
• A drug-device combination.
• A narrow product-specific indication.
• A formulation that depends on a defined particle size or microstructure.
• A settlement agreement restricting launch timing.

For an ANDA sponsor, the principal litigation questions are whether the proposed product practices the asserted claims and whether those claims are valid. Common defenses include lack of novelty, obviousness, inadequate written description, indefiniteness, noninfringement, and failure to satisfy patent-listing requirements.

For a formulation innovator, the strongest patent claims usually cover a technically defined product rather than a broad statement that betamethasone dipropionate is present in a cream. Useful claim elements can include:

• Specific particle-size ranges.
• Defined crystalline form or polymorph.
• Narrow excipient ratios.
• Specified pH, viscosity, or rheology.
• Microstructure or globule-size parameters.
• Spray-performance characteristics.
• Container-closure or dosing configurations.
• A defined relationship between formulation properties and dermal delivery.

How strong is the patent estate for betamethasone dipropionate products?

The molecule-level patent estate is weak because of the age of the active ingredient. The formulation-level estate can be moderate if it protects a reproducible technical feature that competitors cannot easily design around.

Estate component	Relative strength
Core active ingredient	Low
Conventional petrolatum ointment	Low to moderate
Standard oil-in-water cream	Low to moderate
Micronized active with defined performance	Moderate
Proprietary spray or metered delivery system	Moderate to strong
Novel microstructure or controlled-release vehicle	Moderate to strong
Broad indication-only claims	Variable and often vulnerable
Manufacturing process claims	Moderate if difficult to reproduce and well characterized

Patent value depends on claim scope and the likelihood that a generic product will fall within the claims. A narrow claim covering a particular excipient ratio may be easy to design around. A claim tied to measurable product performance may create greater enforcement leverage, but it must remain definite and supported by the specification.

What competitive products and manufacturers shape the market?

The market includes branded and generic products supplied in multiple topical formats. Key commercial products have included:

• Diprolene and Diprolene AF products.
• Sernivo spray.
• Generic betamethasone dipropionate ointments, creams, lotions, gels, and sprays.
• International products marketed under names such as Diprosone, depending on jurisdiction and formulation.

The main competitive variables are price, potency classification, indication coverage, dosage form, application area, cosmetic properties, pharmacy substitution, and payer formulary status. Generic creams and ointments face intense price competition. A differentiated spray, low-residue gel, or sensitive-skin cream has more opportunity to sustain a premium if it demonstrates a clear use advantage.

What revenue exposure and generic launch scenarios should investors consider?

Revenue exposure is highest for a branded product whose value depends on a differentiated vehicle rather than on the corticosteroid molecule. Generic entry can occur through several scenarios:

Launch scenario	Likely impact
Generic conventional ointment	Rapid price erosion in the same dosage form
Generic cream with similar vehicle	Moderate to severe substitution pressure
Generic spray	Slower entry if device, formulation, or patent barriers remain
Alternative dosage form	Partial substitution rather than immediate full erosion
Authorized generic	Faster price competition with controlled brand transition
505(b)(2) reformulation	Potential premium pricing, but higher development costs

A standard generic may win on acquisition price but lose on patient experience. A branded reformulation can defend revenue if it improves adherence, simplifies application, reduces residue, or addresses a site-specific need. Payer coverage remains a major constraint because topical corticosteroids are often treated as interchangeable within potency tiers.

Which geographic markets offer the best formulation opportunities?

The United States offers a mature generic market and a clear FDA pathway, but pricing pressure is high. Europe and other regulated markets offer opportunities for differentiated topical products, although national reimbursement and substitution rules differ. Emerging markets may favor affordable creams and ointments, while climate, packaging, and patient preference can create demand for lotions or sprays.

Geographic development should account for:

• Local potency classification.
• Approved excipient status.
• Preservative restrictions.
• Child-use labeling.
• Dermatological indication requirements.
• Container and labeling standards.
• Local bioequivalence expectations.
• Patent and trademark status by country.

A formulation that is commercially attractive in the United States may require reformulation elsewhere because of excipient acceptance, climate stability, or local device requirements.

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barriers are control of active-particle size, prevention of crystallization, emulsion stability, content uniformity, microbial control, and reproducible filling. Scale-up can change shear exposure, droplet size, viscosity, and drug distribution even when the nominal formula remains unchanged.

Critical process parameters may include:

• Milling or micronization conditions.
• Order of ingredient addition.
• Heating and cooling profile.
• Homogenization energy.
• Mixing time and shear rate.
• Deaeration.
• Filling temperature.
• Hold time before filling.
• Spray or pump assembly conditions.

A successful commercial platform should link these parameters to clinically relevant product attributes. This creates both quality control and intellectual-property value.

Key Takeaways

• Betamethasone dipropionate is a mature active ingredient with limited molecule-level exclusivity.
• The main commercial opportunity is formulation differentiation.
• Ointments maximize occlusion and potency but have weaker cosmetic acceptance.
• Creams offer the broadest market and the best balance between efficacy and usability.
• Lotions, gels, and sprays are attractive for scalp, hairy areas, large surfaces, and patients who reject greasy products.
• Particle size, vehicle microstructure, rheology, and drug distribution are central development variables.
• Preservative reduction, low-residue performance, barrier support, and metered dosing can support premium positioning.
• Conventional products face intense generic and price competition.
• Spray, device, and technically defined vehicle patents can provide stronger protection than conventional cream claims.
• FDA development should anticipate Q1/Q2/Q3 comparability, in vitro release, in vitro permeation, stability, microbiology, and device-performance requirements.

FAQs About Betamethasone Dipropionate Formulation and Commercialization

What is the best excipient for betamethasone dipropionate?

No single excipient is optimal. Petrolatum supports occlusion, propylene glycol can support solubilization and penetration, and emulsion systems improve cosmetic acceptability. The best choice depends on the intended dosage form, application site, irritation profile, and regulatory strategy.

Can betamethasone dipropionate be formulated as a preservative-free cream?

Yes, but the product requires a microbiological control strategy based on the formulation, manufacturing process, and packaging. Airless or unit-dose packaging may be necessary to reduce in-use contamination risk.

Is betamethasone dipropionate suitable for a transdermal patch?

It is generally more suited to localized topical delivery than systemic transdermal delivery. Its low water solubility, high potency, and dermatologic use profile make semisolid or spray vehicles more practical commercial platforms.

Can a new betamethasone dipropionate gel receive 505(b)(2) approval?

A materially different gel or delivery system may be eligible for a 505(b)(2) strategy, depending on the proposed formulation, labeling, reference product, and supporting data. A conventional generic gel may instead be developed through an ANDA pathway.

What is the main cause of betamethasone dipropionate product failure during development?

Common causes include active crystallization, poor content uniformity, emulsion instability, excessive irritation, inadequate preservative performance, poor spray delivery, and failure to demonstrate comparable drug release or dermal delivery.

References

1. United States Pharmacopeia. (2024). Betamethasone dipropionate monograph. United States Pharmacopeial Convention.

2. U.S. Food and Drug Administration. (2023). Diprolene (augmented betamethasone dipropionate) ointment prescribing information. FDA.

3. U.S. Food and Drug Administration. (2023). Sernivo (betamethasone dipropionate) spray prescribing information. FDA.

4. United States Pharmacopeia. (2024). <51> Antimicrobial effectiveness testing. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatological drug product development and testing. FDA.

6. U.S. Food and Drug Administration. (2022). In vitro release test studies for topical drug products submitted in ANDAs. FDA.

7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.